Doer Biologics Reaffirmed as National High-Tech Enterprise and Files IPO Prospectus

Doer Biologics was re-certified as a "National High-tech Enterprise" in 2021 and 2024, following its initial recognition in 2018., this honor is not only a high recognition of the company's long-term commitment to technological innovation in the biopharmaceutical field, but also another important milestone in the company's development process.

In the future, Doer Biologics will strictly carry out all tasks in accordance with the standards of high-tech enterprises. Adhering to the mission of "contributing to human health through diligent and innovative work," it will fully play the exemplary leading role of a high-tech enterprise and strive to build itself into a leading high-tech enterprise within the industry.

Zhejiang Doer Biologics Co., Ltd. was established on April 1, 2014, with a registered capital of 52.12 million yuan. It is a high-tech enterprise under Huadong Medicine (Stock Code: SZ.000963) specializing in the development of innovative biopharmaceuticals. The company's R&D center is located in Hangzhou Medical Port Town. Doer Biologics focuses on developing multi-specific innovative protein drugs based on multi-domain structures to address unmet clinical needs in the fields of metabolic diseases, cancer, and ophthalmology. In 2018, it was recognized as a National High-tech Enterprise, and in 2021, it passed the re-evaluation for this designation while also being selected as a "Near-Unicorn" enterprise in Hangzhou.